New hope for back pain: experimental drug LNK01001 enters final trial phase

NCT ID NCT07237568

Recruiting now Disease control Sponsor: Lynk Pharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the experimental drug LNK01001 can reduce pain and stiffness in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 352 participants will receive either LNK01001 or a placebo twice daily for 16 weeks, then everyone can receive the drug for another 36 weeks. The main goal is to see if more people on LNK01001 achieve at least a 40% improvement in symptoms compared to placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••